- 2024-08-20 01:55抑制剂Flazin|Flazin|100041-05-2|Adamas life|≥98%(以实测数值为准)|BR|5mg
- 2024-08-20 01:55抑制剂FLT3-IN-10|FLT3-IN-10|2088735-51-5|Adamas life|≥98%(以实测数值为准)|BR|1mg
- 2024-08-20 01:55抑制剂FLT3-IN-10|FLT3-IN-10|2088735-51-5|Adamas life|≥98%(以实测数值为准)|BR|25mg
- 2024-08-20 01:55抑制剂FK962|FK962|283167-06-6|Adamas life|≥98%(以实测数值为准)|BR|25mg
- 2024-08-20 01:55抑制剂FK962|FK962|283167-06-6|Adamas life|≥98%(以实测数值为准)|BR|5mg
- 2024-08-20 01:55抑制剂Flazin|Flazin|100041-05-2|Adamas life|≥98%(以实测数值为准)|BR|1mg
- 2024-08-20 01:55抑制剂Filorexant|Filorexant|1088991-73-4|Adamas life|≥98%(以实测数值为准)|BR|1mg
- 2024-08-20 01:55抑制剂Filorexant|Filorexant|1088991-73-4|Adamas life|≥98%(以实测数值为准)|BR|25mg
- 2024-08-20 01:55抑制剂Filorexant|Filorexant|1088991-73-4|Adamas life|≥98%(以实测数值为准)|BR|5mg
- 2024-08-20 01:55抑制剂FK962|FK962|283167-06-6|Adamas life|≥98%(以实测数值为准)|BR|1mg
- 2024-08-20 01:55抑制剂FGFR1/DDR2 inhibitor 1|FGFR1/DDR2 inhibitor 1|2308497-58-5|Adamas life|≥98%(以实测数值为准)|BR|5mg
- 2024-08-20 01:55抑制剂FGFR1/DDR2 inhibitor 1|FGFR1/DDR2 inhibitor 1|2308497-58-5|Adamas life|≥98%(以实测数值为准)|BR|1mg
- 2024-08-20 01:55抑制剂FGFR1/DDR2 inhibitor 1|FGFR1/DDR2 inhibitor 1|2308497-58-5|Adamas life|≥98%(以实测数值为准)|BR|25mg
- 2024-08-20 01:55抑制剂Ferroheme|Ferroheme|14875-96-8|Adamas life|≥98%(以实测数值为准)|BR|5mg
- 2024-08-20 01:55抑制剂Fezolinetant|Fezolinetant|1629229-37-3|Adamas life|≥98%(以实测数值为准)|BR|1mg
- 2024-08-20 01:55抑制剂Fezolinetant|Fezolinetant|1629229-37-3|Adamas life|≥98%(以实测数值为准)|BR|25mg
- 2024-08-20 01:55抑制剂Fezolinetant|Fezolinetant|1629229-37-3|Adamas life|≥98%(以实测数值为准)|BR|5mg
- 2024-08-20 01:55抑制剂Fedovapagon|Fedovapagon|347887-36-9|Adamas life|≥98%(以实测数值为准)|BR|5mg
- 2024-08-20 01:55抑制剂Ferroheme|Ferroheme|14875-96-8|Adamas life|≥98%(以实测数值为准)|BR|100mg
- 2024-08-20 01:55抑制剂Ferroheme|Ferroheme|14875-96-8|Adamas life|≥98%(以实测数值为准)|BR|25mg
